View in EDS

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Saved in:
Bibliographic Details
Title: Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Authors: Williams GS; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Mistry B; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Guillard S; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Ulrichsen JC; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Sandercock AM; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Wang J; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., González-Muñoz A; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Parmentier J; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA., Black C; MedImmune LLC, Gaithersburg, MD 20878, USA., Soden J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK., Freeth J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK., Jovanović J; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Leyland R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Al-Lamki RS; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., Leishman AJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Rust SJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Stewart R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Jermutus L; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Bradley JR; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., Bedian V; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA., Valge-Archer V; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Minter R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Wilkinson RW; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
Source: Oncotarget [Oncotarget] 2016 Oct 18; Vol. 7 (42), pp. 68278-68291.
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 27626702
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Williams+GS%22">Williams GS</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Mistry+B%22">Mistry B</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Guillard+S%22">Guillard S</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Ulrichsen+JC%22">Ulrichsen JC</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Sandercock+AM%22">Sandercock AM</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.<br /><searchLink fieldCode="AU" term="%22González-Muñoz+A%22">González-Muñoz A</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Parmentier+J%22">Parmentier J</searchLink>; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA.<br /><searchLink fieldCode="AU" term="%22Black+C%22">Black C</searchLink>; MedImmune LLC, Gaithersburg, MD 20878, USA.<br /><searchLink fieldCode="AU" term="%22Soden+J%22">Soden J</searchLink>; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK.<br /><searchLink fieldCode="AU" term="%22Freeth+J%22">Freeth J</searchLink>; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK.<br /><searchLink fieldCode="AU" term="%22Jovanović+J%22">Jovanović J</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Leyland+R%22">Leyland R</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Al-Lamki+RS%22">Al-Lamki RS</searchLink>; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.<br /><searchLink fieldCode="AU" term="%22Leishman+AJ%22">Leishman AJ</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Rust+SJ%22">Rust SJ</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Stewart+R%22">Stewart R</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Jermutus+L%22">Jermutus L</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Bradley+JR%22">Bradley JR</searchLink>; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.<br /><searchLink fieldCode="AU" term="%22Bedian+V%22">Bedian V</searchLink>; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA.<br /><searchLink fieldCode="AU" term="%22Valge-Archer+V%22">Valge-Archer V</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Minter+R%22">Minter R</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.<br /><searchLink fieldCode="AU" term="%22Wilkinson+RW%22">Wilkinson RW</searchLink>; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101532965%22">Oncotarget</searchLink> [Oncotarget] 2016 Oct 18; Vol. 7 (42), pp. 68278-68291.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Impact+Journals%22">Impact Journals </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101532965 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1949-2553 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219492553%22">19492553 </searchLink><i>NLM ISO Abbreviation: </i>Oncotarget <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=27626702
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.18632/oncotarget.11943
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 68278
    Titles:
      – TitleFull: Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Williams GS
      – PersonEntity:
          Name:
            NameFull: Mistry B
      – PersonEntity:
          Name:
            NameFull: Guillard S
      – PersonEntity:
          Name:
            NameFull: Ulrichsen JC
      – PersonEntity:
          Name:
            NameFull: Sandercock AM
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: González-Muñoz A
      – PersonEntity:
          Name:
            NameFull: Parmentier J
      – PersonEntity:
          Name:
            NameFull: Black C
      – PersonEntity:
          Name:
            NameFull: Soden J
      – PersonEntity:
          Name:
            NameFull: Freeth J
      – PersonEntity:
          Name:
            NameFull: Jovanović J
      – PersonEntity:
          Name:
            NameFull: Leyland R
      – PersonEntity:
          Name:
            NameFull: Al-Lamki RS
      – PersonEntity:
          Name:
            NameFull: Leishman AJ
      – PersonEntity:
          Name:
            NameFull: Rust SJ
      – PersonEntity:
          Name:
            NameFull: Stewart R
      – PersonEntity:
          Name:
            NameFull: Jermutus L
      – PersonEntity:
          Name:
            NameFull: Bradley JR
      – PersonEntity:
          Name:
            NameFull: Bedian V
      – PersonEntity:
          Name:
            NameFull: Valge-Archer V
      – PersonEntity:
          Name:
            NameFull: Minter R
      – PersonEntity:
          Name:
            NameFull: Wilkinson RW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 10
              Text: 2016 Oct 18
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1949-2553
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 42
          Titles:
            – TitleFull: Oncotarget
              Type: main
ResultId 1